1. Home
  2. WST vs WAT Comparison

WST vs WAT Comparison

Compare WST & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WST
  • WAT
  • Stock Information
  • Founded
  • WST 1923
  • WAT 1958
  • Country
  • WST United States
  • WAT United States
  • Employees
  • WST N/A
  • WAT N/A
  • Industry
  • WST Medical/Dental Instruments
  • WAT Biotechnology: Laboratory Analytical Instruments
  • Sector
  • WST Health Care
  • WAT Industrials
  • Exchange
  • WST Nasdaq
  • WAT Nasdaq
  • Market Cap
  • WST 18.9B
  • WAT 17.8B
  • IPO Year
  • WST N/A
  • WAT 1995
  • Fundamental
  • Price
  • WST $257.82
  • WAT $302.49
  • Analyst Decision
  • WST Strong Buy
  • WAT Hold
  • Analyst Count
  • WST 8
  • WAT 14
  • Target Price
  • WST $329.43
  • WAT $374.07
  • AVG Volume (30 Days)
  • WST 552.4K
  • WAT 582.9K
  • Earning Date
  • WST 10-23-2025
  • WAT 10-31-2025
  • Dividend Yield
  • WST 0.35%
  • WAT N/A
  • EPS Growth
  • WST N/A
  • WAT 10.77
  • EPS
  • WST 6.68
  • WAT 11.09
  • Revenue
  • WST $2,960,200,000.00
  • WAT $3,046,056,000.00
  • Revenue This Year
  • WST $6.28
  • WAT $7.19
  • Revenue Next Year
  • WST $6.02
  • WAT $6.40
  • P/E Ratio
  • WST $37.92
  • WAT $26.89
  • Revenue Growth
  • WST 2.90
  • WAT 5.89
  • 52 Week Low
  • WST $187.43
  • WAT $275.05
  • 52 Week High
  • WST $352.33
  • WAT $423.56
  • Technical
  • Relative Strength Index (RSI)
  • WST 59.73
  • WAT 52.51
  • Support Level
  • WST $253.38
  • WAT $294.96
  • Resistance Level
  • WST $264.06
  • WAT $303.24
  • Average True Range (ATR)
  • WST 5.67
  • WAT 8.88
  • MACD
  • WST 0.57
  • WAT 0.66
  • Stochastic Oscillator
  • WST 72.15
  • WAT 66.28

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About WAT Waters Corporation

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Share on Social Networks: